Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Voriconazole

FDA-approved product (tablet, oral), marketed as Vfend, Voriconazole.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Voriconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Bacterial Infections and Mycoses
  • Candidemia
  • Candidiasis
  • Fungal infectious disease
  • Fusariosis
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC03; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Voriconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Voriconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

    NCT00066599 · start 2003-06

    Registered record
    Registry ID
    NCT00066599
    Conditions
    Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Neutropenia; Sarcoma
    Interventions
    voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-06
    Completion
    2004-06
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm +5 more
    Interventionvoriconazole
    PhasePhase 2
    Registry statusCompleted

  • A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children

    NCT00174473 · start 2003-06

    Registered record
    Registry ID
    NCT00174473
    Conditions
    Neutropenia
    Interventions
    Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2003-06
    Completion
    2005-08
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeutropenia
    InterventionVoriconazole
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Voriconazole to Prevent Systemic Fungal Infections in Children

    NCT00005912 · start 2000-06

    Registered record
    Registry ID
    NCT00005912
    Conditions
    Aspergillosis; Candidiasis; Fungal Diseases; Mycoses
    Interventions
    Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2000-06
    Completion
    2001-01
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis; Candidiasis; Fungal Diseases; Mycoses
    InterventionVoriconazole
    PhasePhase 1
    Registry statusCompleted

  • Voriconazole to Treat Fungal Infections

    NCT00001940 · start 1999-12

    Registered record
    Registry ID
    NCT00001940
    Conditions
    Mycoses
    Interventions
    Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-12
    Completion
    2001-07
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycoses
    InterventionVoriconazole
    PhasePhase 3
    Registry statusCompleted

  • An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

    NCT00001757 · start 1997-11

    Registered record
    Registry ID
    NCT00001757
    Conditions
    Mycoses
    Interventions
    Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-11
    Completion
    2000-07
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycoses
    InterventionVoriconazole
    PhasePhase 3
    Registry statusCompleted